RxDoctor Payments Data

Priyantha Wijewardane, MD

Internal Medicine · Little Rock, ARNPI 1104811108

Payments from drug & device makers

What this record shows

8 manufacturers reported payments, led by Modernatx, Inc. at 33.5% of the total.

$4,382in general payments, 2019–2025

Across 58 payments — averaging $75.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$1K
  • Ipsen Innovation$1K
  • Boehringer Ingelheim$700
  • Astrazeneca UK Limited$374
  • Johnson & Johnson$244
  • Pfizer$192
  • plus $126 from 2 others
$43,604,882in research payments, 2019–2025

Across 5,549 payments — averaging $7858.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$31.9M
  • AstraZeneca$5.6M
  • Astrazeneca UK Limited$2.2M
  • Pfizer$1.7M
  • Merck$898K
  • Janssen Research & Development, LLC$655K
  • plus $594K from 5 others

What the payments were for

  • Travel & lodging$2,20450%
  • Food & beverage$2,17850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,382 in reported general payments places this provider in the 85th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$173,152
Medicare patients
489
Services billed
1,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$14,153
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav16$113
Levetiracetam11$102
Atorvastatin Calcium30$99
Tamsulosin Hcl12$89
Pantoprazole Sodium18$83
Ciprofloxacin Hcl12$76
Levofloxacin21$68
Furosemide18$63
Amlodipine Besylate23$62
ClopidogrelClopidogrel Bisulfate16$53
Prednisone17$52
Metoprolol Tartrate16$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$192$14,15321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →